2023 World Conference on Lung Cancer (Posters)-EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer.

EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer. - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the clinical experience of neoadjuvant chemo-immunotherapy for stage III non-small cell lung cancer (NSCLC) and evaluated the role of PD-L1 expression as a predictive marker of achieving pathological complete response (pCR) and major pathological response (MPR). The study included 61 patients who underwent neoadjuvant chemo-immunotherapy followed by definitive surgery. Radiological partial response was achieved in 95% of patients. Among patients with squamous cell lung cancer and PD-L1 expression over 50%, 80% achieved pCR and 20% achieved MPR. In patients with non-squamous NSCLC and PD-L1 expression between 1-49%, 38.5% achieved pCR and 7.7% achieved MPR. Among patients with PD-L1 levels less than 1%, 37.5% achieved pCR and MPR. In the non-squamous NSCLC group with PD-L1 levels over 50%, 66.7% achieved pCR and 22.3% achieved MPR. The study concluded that neoadjuvant chemo-immunotherapy leads to the achievement of pCR and MPR, resulting in improved event-free survival and overall survival. Notably, patients with squamous cell lung cancer and PD-L1 expression over 50% benefit the most from this treatment approach, achieving an 80% pCR and 100% MPR rate. Further research is needed to confirm these findings.

Asset Subtitle

Yana Akhmadiyarova

Meta Tag

Speaker Yana Akhmadiyarova

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemo-immunotherapy

stage III non-small cell lung cancer

NSCLC

PD-L1 expression

predictive marker

pathological complete response

pCR

major pathological response

MPR

squamous cell lung cancer